BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more
BEXIMCO PHARMA.GDR REGS 1 (R2WA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, BEXIMCO PHARMA.GDR REGS 1 (R2WA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BEXIMCO PHARMA.GDR REGS 1 - Net Assets Trend (None–None)
This chart illustrates how BEXIMCO PHARMA.GDR REGS 1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BEXIMCO PHARMA.GDR REGS 1 (None–None)
The table below shows the annual net assets of BEXIMCO PHARMA.GDR REGS 1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BEXIMCO PHARMA.GDR REGS 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BEXIMCO PHARMA.GDR REGS 1 Competitors by Market Cap
The table below lists competitors of BEXIMCO PHARMA.GDR REGS 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VESTUM AB AK
F:W0S
|
$128.00 Million |
|
Young Optics Inc
TW:3504
|
$128.01 Million |
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
$128.08 Million |
|
EASY HOLDINGS Co. Ltd
KQ:035810
|
$128.08 Million |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
$127.87 Million |
|
Acepodia, Inc.
TWO:6976
|
$127.76 Million |
|
Diana Shipping Inc.
NYSE:DSX
|
$127.61 Million |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
$127.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BEXIMCO PHARMA.GDR REGS 1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BEXIMCO PHARMA.GDR REGS 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BEXIMCO PHARMA.GDR REGS 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BEXIMCO PHARMA.GDR REGS 1's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BEXIMCO PHARMA.GDR REGS 1 (R2WA) | €- | N/A | N/A | $127.97 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |